DK2008657T3 - Anvendelse af rapamycinderivater ved karforandringer - Google Patents

Anvendelse af rapamycinderivater ved karforandringer

Info

Publication number: DK2008657T3
Authority: DK; Denmark
Prior art keywords: rapamycin derivatives; vascular changes; rapamycin; vascular; deoxyspergualine
Prior art date: 1996-03-27

Application number

DK08017336.2T

Other languages

Danish (da)

English (en)

Inventor

Walter Schuler

Gisbert Weckbecker

Hans-Guenter Zerwes

Hessel Johannes Schuurmann

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-27

Filing date

1997-03-26

Publication date

2013-07-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2008657(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-26 Application filed by Novartis Ag filed Critical Novartis Ag

2013-07-22 Application granted granted Critical

2013-07-22 Publication of DK2008657T3 publication Critical patent/DK2008657T3/da

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
230000002792 vascular Effects 0.000 title 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
208000024248 Vascular System injury Diseases 0.000 abstract 1
208000012339 Vascular injury Diseases 0.000 abstract 1
206010053648 Vascular occlusion Diseases 0.000 abstract 1
229960002170 azathioprine Drugs 0.000 abstract 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000000265 leukocyte Anatomy 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
229960000485 methotrexate Drugs 0.000 abstract 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 abstract 1
229960004866 mycophenolate mofetil Drugs 0.000 abstract 1
229960000951 mycophenolic acid Drugs 0.000 abstract 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
229960001967 tacrolimus Drugs 0.000 abstract 1
230000008719 thickening Effects 0.000 abstract 1
208000021331 vascular occlusion disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK08017336.2T 1996-03-27 1997-03-26 Anvendelse af rapamycinderivater ved karforandringer DK2008657T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9606452.2A GB9606452D0 (en)	1996-03-27	1996-03-27	Organic compounds
EP01116262A EP1149581A3 (en)	1996-03-27	1997-03-26	Use of rapamycin derivatives in vasculopathies and xenotransplantation

Publications (1)

Publication Number	Publication Date
DK2008657T3 true DK2008657T3 (da)	2013-07-22

Family

ID=10791127

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08017336.2T DK2008657T3 (da)	1996-03-27	1997-03-26	Anvendelse af rapamycinderivater ved karforandringer
DK97915441T DK0893996T3 (da)	1996-03-27	1997-03-26	Anvendelse af et rapamycinderivat til behandling af karsygdomme og xenotransplantationer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK97915441T DK0893996T3 (da)	1996-03-27	1997-03-26	Anvendelse af et rapamycinderivat til behandling af karsygdomme og xenotransplantationer

Country Status (29)

Country	Link
US (5)	US6384046B1 (2)
EP (3)	EP2008657B1 (2)
JP (2)	JP2000507226A (2)
KR (2)	KR20070083654A (2)
CN (1)	CN1124135C (2)
AT (1)	ATE224194T1 (2)
AU (1)	AU716514B2 (2)
BR (1)	BR9708358A (2)
CA (1)	CA2247275C (2)
CY (1)	CY2404B1 (2)
CZ (1)	CZ292483B6 (2)
DE (1)	DE69715611T2 (2)
DK (2)	DK2008657T3 (2)
ES (2)	ES2184078T3 (2)
GB (1)	GB9606452D0 (2)
HU (1)	HU226422B1 (2)
ID (1)	ID17195A (2)
IL (1)	IL125812A (2)
MY (1)	MY117798A (2)
NO (1)	NO316667B1 (2)
NZ (1)	NZ331463A (2)
PL (1)	PL187732B1 (2)
PT (2)	PT2008657E (2)
RU (1)	RU2214247C2 (2)
SI (1)	SI2008657T1 (2)
SK (1)	SK284343B6 (2)
TR (1)	TR199801919T2 (2)
WO (1)	WO1997035575A1 (2)
ZA (1)	ZA972719B (2)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
PT956034E (pt)	1996-07-30	2002-12-31	Novartis Ag	Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US6890546B2 (en)	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
DE60044717D1 (de) *	1999-05-10	2010-09-02	Paolo Brenner	Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US20070032853A1 (en) †	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US6790228B2 (en)	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US20070141107A1 (en) *	2000-03-15	2007-06-21	Orbusneich Medical, Inc.	Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US8088060B2 (en)	2000-03-15	2012-01-03	Orbusneich Medical, Inc.	Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) *	2001-03-15	2003-12-11	Kutryk Michael J. B.	Medical device with coating that promotes cell adherence and differentiation
US8460367B2 (en) *	2000-03-15	2013-06-11	Orbusneich Medical, Inc.	Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU2001245734A1 (en)	2000-03-15	2001-09-24	Orbus Medical Technologies Inc.	Coating that promotes endothelial cell adherence
US9522217B2 (en)	2000-03-15	2016-12-20	Orbusneich Medical, Inc.	Medical device with coating for capturing genetically-altered cells and methods for using same
US20070055367A1 (en) *	2000-03-15	2007-03-08	Orbus Medical Technologies, Inc.	Medical device with coating that promotes endothelial cell adherence and differentiation
US20050002986A1 (en) *	2000-05-12	2005-01-06	Robert Falotico	Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en)	2000-05-12	2007-11-27	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en)	2000-05-12	2012-08-07	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
EP1709974A3 (en) *	2000-06-16	2006-12-06	Wyeth	Method of treating cardiovascular disease using rapamycin
US20020013335A1 (en) *	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
CA2424029C (en)	2000-09-29	2008-01-29	Cordis Corporation	Coated medical devices
MX368013B (es) *	2001-02-19	2019-09-13	Novartis Ag	Tratamiento de cáncer.
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US6939376B2 (en)	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en)	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
AP2004003113A0 (en) *	2002-02-22	2004-09-30	Prophy Med Ab	Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) *	2002-04-24	2004-02-05	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
CN1655738A (zh) *	2002-05-20	2005-08-17	奥勃斯医学技术股份有限公司	可植入的药物洗脱医疗装置
US8109987B2 (en)	2003-04-14	2012-02-07	Tryton Medical, Inc.	Method of treating a lumenal bifurcation
US7279174B2 (en) *	2003-05-08	2007-10-09	Advanced Cardiovascular Systems, Inc.	Stent coatings comprising hydrophilic additives
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US7220755B2 (en) *	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en)	2003-11-19	2015-08-25	Advanced Cardiovascular Systems, Inc.	Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
TW200605910A (en) *	2004-04-30	2006-02-16	Orbus Medical Technologies Inc	Medical device with coating for capturing genetically-altered cells and methods for using same
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en)	2004-09-24	2011-03-08	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
EP1838288A4 (en) *	2004-12-20	2010-08-04	Ariad Pharma Inc	THERAPEUTIC MATERIALS AND METHODS
WO2007059106A2 (en)	2005-11-14	2007-05-24	Ariad Gene Therapeutics, Inc.	Administration of mntor inhibitor to treat patients with cancer
EP1948079A1 (en) *	2005-11-17	2008-07-30	Access Plus Co., Ltd.	A tube for connecting marteriovenous and interposition for medical operation
US20070173923A1 (en) *	2006-01-20	2007-07-26	Savage Douglas R	Drug reservoir stent
EP2083834B1 (en)	2006-09-13	2017-06-21	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en)	2006-10-20	2008-04-24	Biosensors International Group	Drug-delivery endovascular stent and method of use
US8067055B2 (en) *	2006-10-20	2011-11-29	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method of use
US20080103584A1 (en)	2006-10-25	2008-05-01	Biosensors International Group	Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) *	2007-09-19	2009-12-07	삼성전기주식회사	초광각 광학계
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
EP2219700B1 (en)	2007-11-14	2024-03-20	Biosensors International Group, Ltd.	Automated coating apparatus and method
US8921642B2 (en) *	2008-01-11	2014-12-30	Massachusetts Eye And Ear Infirmary	Conditional-stop dimerizable caspase transgenic animals
US20100086579A1 (en) *	2008-10-03	2010-04-08	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US8382818B2 (en)	2009-07-02	2013-02-26	Tryton Medical, Inc.	Ostium support for treating vascular bifurcations
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
UA104738C2 (ru)	2011-05-18	2014-03-11	Олег Миколайович Лазаренко	Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) *	2011-08-30	2013-08-28	成都摩尔生物医药有限公司	一种依维莫司的合成方法
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
KR101723265B1 (ko)	2013-08-16	2017-04-04	가톨릭대학교 산학협력단	mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
SG11201602232UA (en)	2013-09-24	2016-04-28	Giner Inc	System for gas treatment of a cell implant
JP6529012B2 (ja)	2013-10-08	2019-06-12	エイアイ・セラピューティクス・インコーポレーテッド	リンパ脈管筋腫症の処置のためのラパマイシン
US10307371B2 (en)	2014-02-11	2019-06-04	AI Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
MX2016010373A (es)	2014-02-11	2016-11-30	Lam Therapeutics Inc	Rapamicina para el tratamiento de linfangioleiomiomatosis.
NZ724756A (en)	2014-04-04	2023-07-28	Ai Therapeutics Inc	An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru)	2014-10-07	2020-09-24	ЭйАй ТЕРАПЬЮТИКС, ИНК.	Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
MA40910A (fr)	2014-11-07	2017-09-12	Civitas Therapeutics Inc	Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en)	2015-02-10	2016-08-18	Lam Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
EP3496712A1 (en)	2016-08-10	2019-06-19	The Board of Regents of The University of Texas System	Topical rapamycin therapy
EP3515517B1 (en)	2016-09-19	2022-02-16	Biotronik AG	Polymer-free drug eluting vascular stents
AU2017361260B2 (en)	2016-11-15	2023-06-08	Giner, Inc.	Percutaneous gas diffusion device suitable for use with a subcutaneous implant
CN109996569B (zh)	2016-12-22	2022-05-03	百多力股份公司	用于医疗装置的药物释放涂层及其制备方法
CN110831656A (zh)	2017-05-04	2020-02-21	吉纳生命科学公司	稳健的可植入气体递送装置和方法、系统以及包括该装置的装置
AR112834A1 (es)	2017-09-26	2019-12-18	Novartis Ag	Derivados de rapamicina
HRP20250197T1 (hr)	2018-12-18	2025-04-11	Novartis Ag	Derivati rapamicina
US20200261427A1 (en)	2019-02-20	2020-08-20	Al Therapeutics, Inc.	Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en) *	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
US5364612A (en) *	1991-05-06	1994-11-15	Immunomedics, Inc.	Detection of cardiovascular lesions
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
CA2086642C (en) *	1992-01-09	2004-06-15	Randall E. Morris	Method of treating hyperproliferative vascular disease
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
CA2094858C (en) *	1992-04-28	2004-06-15	Robert D. Mitchell	Method of treating hyperproliferative vascular disease
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
US5283257A (en) *	1992-07-10	1994-02-01	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating hyperproliferative vascular disease
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
SK78196A3 (en) *	1993-12-17	1997-02-05	Sandoz Ag	Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US6265427B1 (en) *	1995-06-07	2001-07-24	The Proctor & Gamble Company	Pharmaceutical composition for the method of treating leukemia
US5985890A (en) *	1995-06-09	1999-11-16	Novartis Ag	Rapamycin derivatives
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds

1996
- 1996-03-27 GB GBGB9606452.2A patent/GB9606452D0/en active Pending
1997
- 1997-03-25 MY MYPI97001258A patent/MY117798A/en unknown
- 1997-03-25 ID IDP970980A patent/ID17195A/id unknown
- 1997-03-26 TR TR1998/01919T patent/TR199801919T2/xx unknown
- 1997-03-26 CZ CZ19983070A patent/CZ292483B6/cs not_active IP Right Cessation
- 1997-03-26 PT PT80173362T patent/PT2008657E/pt unknown
- 1997-03-26 EP EP08017336.2A patent/EP2008657B1/en not_active Expired - Lifetime
- 1997-03-26 BR BR9708358A patent/BR9708358A/pt not_active Application Discontinuation
- 1997-03-26 WO PCT/EP1997/001548 patent/WO1997035575A1/en not_active Ceased
- 1997-03-26 IL IL12581297A patent/IL125812A/en not_active IP Right Cessation
- 1997-03-26 ES ES97915441T patent/ES2184078T3/es not_active Expired - Lifetime
- 1997-03-26 KR KR1020077008212A patent/KR20070083654A/ko not_active Withdrawn
- 1997-03-26 PL PL97328659A patent/PL187732B1/pl unknown
- 1997-03-26 HU HU0001267A patent/HU226422B1/hu unknown
- 1997-03-26 DK DK08017336.2T patent/DK2008657T3/da active
- 1997-03-26 DK DK97915441T patent/DK0893996T3/da active
- 1997-03-26 AU AU22918/97A patent/AU716514B2/en not_active Expired
- 1997-03-26 NZ NZ331463A patent/NZ331463A/en not_active IP Right Cessation
- 1997-03-26 JP JP9532077A patent/JP2000507226A/ja not_active Withdrawn
- 1997-03-26 CN CN97193278A patent/CN1124135C/zh not_active Expired - Lifetime
- 1997-03-26 SI SI9730801T patent/SI2008657T1/sl unknown
- 1997-03-26 ES ES08017336T patent/ES2421455T3/es not_active Expired - Lifetime
- 1997-03-26 SK SK1327-98A patent/SK284343B6/sk not_active IP Right Cessation
- 1997-03-26 AT AT97915441T patent/ATE224194T1/de not_active IP Right Cessation
- 1997-03-26 DE DE69715611T patent/DE69715611T2/de not_active Revoked
- 1997-03-26 CA CA2247275A patent/CA2247275C/en not_active Expired - Lifetime
- 1997-03-26 EP EP01116262A patent/EP1149581A3/en not_active Withdrawn
- 1997-03-26 PT PT97915441T patent/PT893996E/pt unknown
- 1997-03-26 KR KR1020057005463A patent/KR100836971B1/ko not_active Expired - Lifetime
- 1997-03-26 EP EP97915441A patent/EP0893996B1/en not_active Revoked
- 1997-03-26 RU RU98119312/14A patent/RU2214247C2/ru active
- 1997-03-27 ZA ZA972719A patent/ZA972719B/xx unknown
1998
- 1998-09-18 NO NO19984340A patent/NO316667B1/no not_active IP Right Cessation
2000
- 2000-11-14 US US09/712,359 patent/US6384046B1/en not_active Expired - Lifetime
2002
- 2002-03-07 US US10/092,639 patent/US20020127248A1/en not_active Abandoned
2004
- 2004-01-08 CY CY0400004A patent/CY2404B1/xx unknown
2008
- 2008-12-10 JP JP2008314494A patent/JP5124431B2/ja not_active Expired - Lifetime
2010
- 2010-03-01 US US12/715,007 patent/US20100152105A1/en not_active Abandoned
2012
- 2012-01-24 US US13/357,199 patent/US20120177690A1/en not_active Abandoned
2014
- 2014-03-05 US US14/197,368 patent/US20140187574A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100152105A1 (en)	2010-06-17
PL187732B1 (pl)	2004-09-30
CZ307098A3 (cs)	1999-01-13
EP0893996B1 (en)	2002-09-18
ATE224194T1 (de)	2002-10-15
PT2008657E (pt)	2013-07-12
PL328659A1 (en)	1999-02-15
CN1124135C (zh)	2003-10-15
US20020127248A1 (en)	2002-09-12
TR199801919T2 (xx)	1999-02-22
EP1149581A3 (en)	2003-12-03
MY117798A (en)	2004-08-30
ES2184078T3 (es)	2003-04-01
DK0893996T3 (da)	2002-12-09
KR20050038656A (ko)	2005-04-27
RU2214247C2 (ru)	2003-10-20
CA2247275C (en)	2011-10-11
EP2008657B1 (en)	2013-04-24
US6384046B1 (en)	2002-05-07
KR20070083654A (ko)	2007-08-24
SI2008657T1 (sl)	2013-07-31
DE69715611T2 (de)	2003-05-22
NZ331463A (en)	2001-10-26
CA2247275A1 (en)	1997-10-02
HUP0001267A3 (en)	2002-01-28
WO1997035575A1 (en)	1997-10-02
EP0893996A1 (en)	1999-02-03
IL125812A0 (en)	1999-04-11
SK132798A3 (en)	1999-03-12
CY2404B1 (en)	2004-09-10
US20140187574A1 (en)	2014-07-03
NO984340D0 (no)	1998-09-18
GB9606452D0 (en)	1996-06-05
DE69715611D1 (de)	2002-10-24
EP1149581A2 (en)	2001-10-31
IL125812A (en)	2001-12-23
ZA972719B (en)	1998-09-28
JP2000507226A (ja)	2000-06-13
NO316667B1 (no)	2004-03-29
NO984340L (no)	1998-09-18
KR100836971B1 (ko)	2008-06-10
JP5124431B2 (ja)	2013-01-23
SK284343B6 (sk)	2005-02-04
HU226422B1 (en)	2008-12-29
EP2008657A2 (en)	2008-12-31
HUP0001267A2 (hu)	2000-11-28
AU2291897A (en)	1997-10-17
JP2009102349A (ja)	2009-05-14
EP2008657A3 (en)	2009-02-04
HK1018688A1 (en)	1999-12-30
ES2421455T3 (es)	2013-09-02
BR9708358A (pt)	1999-08-03
PT893996E (pt)	2002-12-31
ID17195A (id)	1997-12-11
US20120177690A1 (en)	2012-07-12
CZ292483B6 (cs)	2003-09-17
AU716514B2 (en)	2000-02-24
CN1214631A (zh)	1999-04-21

Publication	Publication Date	Title
DK2008657T3 (da)	2013-07-22	Anvendelse af rapamycinderivater ved karforandringer
DK0745074T3 (da)	2002-04-22	4-Aminoderivater af mycophenolsyre med immunsuppressiv virkning
FI963101A7 (fi)	1996-08-06	Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
ES2054627T3 (es)	1994-08-16	Indolinas 3,3-disustituidas.
DK0784683T3 (da)	2001-03-19	TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
DE69121608D1 (de)	1996-10-02	Verfahren zur Vorsulfidierung von Hydrobehandlungs-, Hydrokrackung- oder Restgasbehandlungskatalysatoren
TR200001171T2 (tr)	2000-10-23	Nikotinik asetilkolin reseptörlerinde kolinerjik ligandlar olarak heteroaril diazasikloalkalinler
EA200300027A1 (ru)	2003-06-26	Способ лечения сердечно-сосудистых заболеваний
DE69003202D1 (de)	1993-10-14	Hochfeste, hitzebeständige, niedrig legierte Stähle.
DE60045870D1 (de)	2011-06-01	Monoklonaler antikörper, hybridoma, immuntestverfahren und diagnosekit
ATE485054T1 (de)	2010-11-15	Pharmazeutische oder nährungsmittelzusammensetzung für die behandlung von pathologien die assoziert sind mit einem transplantatabstoss
Rajabally et al.	2004	Disorder resembling Guillain–Barre syndrome on initiation of statin therapy
ATE188208T1 (de)	2000-01-15	Diacylsubstituierte guanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
DE602004017838D1 (de)	2009-01-02	Verfahren zur herstellung von 6-ä(4,5-dihydro-1h-imidazol-2-yl)amino-ü-7-methyl-1h-benzimidazol-4-carbonitrile und dessen bevorzugte salzform
DK0745072T3 (da)	1999-01-18	4-aminoderivater af 5-substitueret mycophenolsyre
FI963222A0 (fi)	1996-08-16	6-substituoitu 4-amino-mykofenolihappo ja sen johdannaiset, joilla on immunosuppressiivista aktiivisuutta
ATE274920T1 (de)	2004-09-15	Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
RU97118099A (ru)	1999-04-20	Способ лечения психопатологических синдромов пограничного уровня сосудисто- склеротического генеза
RU2000124058A (ru)	2002-08-10	Способ лечения миопии
RU96119633A (ru)	1998-12-20	Способ лечения аметропий и разницы в функциональных показателях правого и левого глаза по святковской т.я.
Nguyet	2024	An Investigation into Strategies to Develop Pronunciation Skills for First-year Non-English-majored Students at Thuongmai University
Brush	1999	Change and Challenge ICN During the 1970s & 1980s
Pioli	1993	Reactivation failure in infants: A processing analysis.
ATE223730T1 (de)	2002-09-15	Verwendung von molekulargewichtserweitertem hirudin als antikoagulans bei der extrakorporalen nierenersatztherapie
RU2002110647A (ru)	2003-12-10	Способ хирургической коррекции внепеченочной формы портальной гипертензии у детей